Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Date of authorisation: 11/05/1998, Revision: 49, Status: Authorised

Guidance on the anonymisation of protected personal data and assessment of commercially confidential information during the preparation of RMPs (main body and annexes 4 and 6)

Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Edurant, rilpivirine, Date of authorisation: 28/11/2011, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Effentora, fentanyl, Date of authorisation: 04/04/2008, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Fabhalta, Iptacopan, Date of authorisation: 17/05/2024, Revision: 4, Status: Authorised

Template for the qualified person's (QP) declaration concerning good manufacturing practice compliance of active substance manufacture "The QP declaration template" - Scientific guideline

Medical devices

Questions & answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies

Questions & answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies - tracked changes